Navigation Links
Vicept Therapeutics Announces Positive Clinical Study Results of V-101 for the Treatment of the Erythema of Rosacea
Date:8/5/2010

meritus, University of Pennsylvania and lead investigator. "To date, there are no FDA approved treatments for this manifestation of the disease and V-101 offers a novel approach that, if successful, would address this unmet medical need."

About Rosacea

Rosacea is a common, chronic condition of the skin that is estimated to affect more than 16 million people in the United States and more than 45 million people worldwide. The disorder appears most commonly in fair-skinned individuals of northern, eastern European or Celtic origin between 30 and 50 years of age, and women are affected 2-3x more often than men. Rosacea typically occurs in a central facial distribution (cheeks, nose, forehead, and chin) and is most commonly associated with a history of flushing or blushing (transient erythema), persistent facial redness (nontransient erythema), papules and/or pustules which may resemble acne, and facial telangiectasias (dilated blood vessels). Each of these signs may be transient or persistent and may occur individually or in combination.

About Vicept

Vicept Therapeutics, Inc. is a privately held specialty pharmaceutical company with a mission to develop the first effective topically applied therapy directed toward the erythema of rosacea and other disorders characterized by redness and or flushing of the skin. The company is also pursuing the development of topical agents for the treatment and prevention of a number of medical and cosmetic indications including bruising of the skin.  The company is based in Malvern, Pennsylvania and more information can be found by visiting the company's website at

SOURCE Vicept Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO
2. United Therapeutics Corporation to Announce Second Quarter 2010 Financial Results Before Market Open on Wednesday, July 28, 2010
3. Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
4. Talecris Biotherapeutics to Report Second Quarter 2010 Financial Results
5. Talecris Biotherapeutics Announces Premerger HSR Filing
6. Lafmin Morgan Joins Talecris Biotherapeutics as Vice President, U.S. Product Management
7. Northwest Biotherapeutics Raises Funding and Proceeds With Balance Sheet Restructuring
8. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
9. United Therapeutics and Lees Pharmaceutical Sign Remodulin Distribution Agreement for China
10. Precision Therapeutics Growing Rapidly as it Augments Research and Development Efforts
11. Sirnaomics Receives Two SBIR Grants from NIH for Developing siRNA Therapeutics to Treat Glioblastoma and Influenza Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Calif. , July 29, 2014  ImmunoClin ... in personalized medicine, treatment of infectious diseases as ... of prognosis and prevention of pathologies like cardiovascular ... August 1, 2014, ImmunoClin Corporation will complete the ... Washington, D.C. , a key center ...
(Date:7/29/2014)... Tenn. (PRWEB) July 29, 2014 ... in biomass feedstock supply innovation and supply chain ... proprietary feedstock management systems, Energy Grange™ and Supply ... of R&D and in-the-field testing aimed at consolidating ... offering benefits to landowners, farmers and feedstock end ...
(Date:7/29/2014)... 2014  United Therapeutics Corporation (NASDAQ: ... results for the second quarter ended June 30, ... that our medicines are reaching increasing numbers ... (PAH)," said Martine Rothblatt, Ph.D., United Therapeutics, ... launch this quarter of our extended-release tablet ...
(Date:7/29/2014)... The prestigious "Discovery or Exploration in History Award" ... Juliana Hillis and Kaylie O’Connell, students at Stoneham High ... Egg, Everything: America’s First IVF Baby". This project was ... History Day program during a week-long final competition judged ... D.C. , The growing popularity of the assisted reproductive ...
Breaking Biology Technology:ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 2ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 3Genera Energy Introduces Proprietary Feedstock Management Systems 2Genera Energy Introduces Proprietary Feedstock Management Systems 3Genera Energy Introduces Proprietary Feedstock Management Systems 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 3
... CINCINNATI, June 16, 2011 Kendle (Nasdaq: ... research organization, today announced several of its senior ... issues at the Drug Information Association (DIA) 47th ... experts will address key topics, including the benefits ...
... , New Generation of the Ziehm Vision RFD ... Imaging has launched a new generation of the Ziehm Vision,RFD ... allows it to be used over an almost unlimited period,of ... ORs.,Thanks to its mobility and significantly lower investment costs,the Ziehm ...
... 2011 NewCardio, Inc., (OTC BB: NWCI) a ... of its recent medical and technical submissions have ... Annual International Conference of the IEEE Engineering in ... The two papers: ,Wireless Monitoring of Reconstructed 12-Lead ...
Cached Biology Technology:Kendle Experts to Address Key Industry Issues at Drug Information Association 47th Annual Meeting 2Kendle Experts to Address Key Industry Issues at Drug Information Association 47th Annual Meeting 3SVS 2011: Ziehm Imaging Presents Latest Mobile C-armTechnology for Intraoperative use 2NewCardio Selected to Present at 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society 2NewCardio Selected to Present at 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society 3NewCardio Selected to Present at 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society 4
(Date:7/28/2014)... pinpointed a mechanism in part of the brain that is ... to both type 1 and type 2 diabetes. The findings ... of the National Academies of Sciences . , "We,ve ... part of the hypothalamus known as the ventromedial nucleus ... levels in the blood," said lead author Sabrina Diano, professor ...
(Date:7/28/2014)... The genome of Solanum pennellii , a wild ... an international group of researchers including the labs headed ... UC Davis Department of Plant Biology. The new genome ... , The work, published July 27 in the journal ... and colleagues at Aachen University in Germany. The UC ...
(Date:7/28/2014)... for Alzheimer,s disease and other forms of dementia, but ... treatment. , University of Washington bioengineers have a designed ... of the body,s normal proteins into a state that,s ... disease, Type 2 diabetes and Lou Gehrig,s disease. The ... their normal state into an abnormally folded form by ...
Breaking Biology News(10 mins):Glucose 'control switch' in the brain key to both types of diabetes 2New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3
... DigitalPersona, Inc., a leader in fingerprint identity ... Solutions Company is now offering U.are.U fingerprint sensors ... modular point-of-sale (POS) workstation, the Stingray JS-950. The ... can be attached to either side of the ...
... land degradation in dryland regions continuing to worsen, ... on scientist-recommended indicators for monitoring and assessing desertification ... landmark agreement was reached after two weeks of ... attending the Ninth Session of the Conference of ...
... Israel, October 7, 2009 H2 Blocker drugs, such as ... reflux (heartburn), pose no significant risks for the fetus according ... University of the Negev. The study published in the ... the safety of the fetus when H2 blocker drugs ...
Cached Biology News:Panasonic Offers U.are.U(R) Fingerprint Sensor From DigitalPersona on Stingray JS-950 Point-of-Sale Workstations 2Satellite data instrumental in combating desertification 2Satellite data instrumental in combating desertification 3Heartburn drugs deemed safe for fetuses according to Ben-Gurion University researchers 2
Purified Mouse anti-Hu LAT (pY226) Storage Temperature: Refrigerate(2 to 8C)...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile, Molecular Biology Grade...
... the most comprehensive, cost-effective solution to ... incorporated unprecedented quality into both our ... proven detection chemistries and antibodies that ... protocol. It also includes our competitively ...
...
Biology Products: